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Today the traditional treatment algorithm for 
relapsing-remitting multiple sclerosis (RRMS) is to 
initiate treatment with a moderately effective inject-
able or oral disease-modifying therapy (DMT) and 
to escalate treatment to a highly effective DMT in 
patients with a suboptimal treatment response.1 A 
smaller fraction of highly active patients has been 
treated with a highly effective treatment as the ini-
tial therapy, typically fingolimod or natalizumab.2
Whereas the effect of fingolimod and natali-
zumab is not maintained after cessation of ther-
apy, which in some patients may even result in 
rebound disease activity,3 some new highly effec-
tive therapies can show prolonged treatment 
effects in a proportion of patients after a short 
course of treatment. Such therapies have been 
named pulsed immunosuppressive therapies or 
pulsed immune reconstitution therapies and are 
thought to induce long-term qualitative benefi-
cial changes in the adaptive immune system.4
The strongest immune reconstitution therapy is 
probably intense immunosuppression with stem 
cell support or autologous haematopoietic stem 
cell transplantation (HSCT), which, however, 
differs from the before-mentioned therapies by 
being administered only as a single treatment 
course.5 HSCT is, therefore, only briefly men-
tioned in the present article.
Pulsed immune reconstitution therapy  
in multiple sclerosis
Per Soelberg Sorensen and Finn Sellebjerg
Abstract: Whereas drugs used for maintenance/escalation therapy do not maintain their 
beneficial effect after cessation of therapy, some new highly effective therapies can show 
prolonged treatment effects after a short treatment course. Such therapies have been named 
pulsed immune reconstitution therapies or pulsed immunosuppressive therapies, and typical 
representatives are alemtuzumab and cladribine. Autologous haematopoietic stem cell 
transplantation could be considered as the strongest immune reconstitution therapy. Both 
alemtuzumab and cladribine induce depletion of lymphocytes, and a common mechanism of 
action is preferential depletion of class-switched and unswitched memory B-cells. Whereas 
CD-19+ B-lymphocytes repopulate within 6 months, CD4+ T-cells repopulate at a slower rate, 
taking 1–2 years to reach the lower level of normal. In general, the depletion of lymphocytes is 
more profound and the repletion of T-cells is slower after alemtuzumab than after cladribine 
treatment. Both drugs have a strong effect on relapses and magnetic resonance imaging 
(MRI) activity, and reduce disability worsening. The therapeutic effect is maintained beyond 
the period of active treatment in a large proportion of patients, which is best documented for 
alemtuzumab. Adverse effects include reactivation of latent infections such as tuberculosis 
and risk of herpes zoster. The main disadvantage in alemtuzumab-treated patients is the risk 
of secondary immune-mediated disorders. Pulsed immune reconstitution therapy is an option 
as initial therapy in relapsing-remitting multiple sclerosis patients with high disease activity 
and in patients on treatment with another disease-modifying therapy with significant relapse 
and/or MRI activity.
Keywords: alemtuzumab, autologous haematopoietic stem cell transplantation, cladribine, 
multiple sclerosis, MS, multiple sclerosis treatment, pulsed immune reconstitution therapy
Received: 8 October 2018; revised manuscript accepted: 2 February 2019.
Correspondence to: 
Per Soelberg Sorensen 
Department of Neurology 
2082, Danish Multiple 
Sclerosis Center, 
University of Copenhagen, 
Rigshospitalet, 9, 
Blegdamsvej, DK-2100 
Copenhagen, Denmark 
pss@rh.dk
Finn Sellebjerg 
Department of Neurology, 
Danish Multiple Sclerosis 
Center, University 
of Copenhagen, 
Rigshospitalet, 
Copenhagen, Denmark
836913 TAN0010.1177/1756286419836913Therapeutic Advances in Neurological DisordersPS Sorensen and F Sellebjerg
review-article20192019
Review
Therapeutic Advances in Neurological Disorders 12
2 journals.sagepub.com/home/tan
A proposal for categorization of DMTs divides 
treatments into drugs for maintenance/escalation 
therapy and into pulsed immune reconstitution 
therapies. The principles of maintenance/escala-
tion therapy and pulse immune reconstitution 
therapy is shown in Figure 1.
Immunomodulatory drugs and drugs for chronic 
immunosuppression need to be administered con-
tinuously to maintain their therapeutic efficacy, 
while pulsed immune reconstitution therapies are 
administered in short courses and in many patients 
the therapeutic efficacy is maintained well beyond 
the active treatment period.2 Some drugs may be 
difficult to place according to the classification 
– for example, ocrelizumab, which might be either 
called a chronic immunosuppressive or pulsed 
immune reconstitution therapy. Ocrelizumab is 
administered as pulsed therapy every 6 months, 
but it has not been fully elucidated whether the 
therapeutic efficacy is maintained over a period 
beyond the next planned administration.6
Mitoxantrone represents drugs causing nonselec-
tive immunosuppression and has been used as 
induction therapy.7–9 The difference between an 
induction therapy and a pulsed immune reconsti-
tution therapy is that induction therapy involves 
administration of a highly effective drug (e.g. 
mitoxantrone) after which the treatment is 
Figure 1. Principles of maintenance/escalation therapy (A) pulsed immune reconstitution therapy (B)
MRI, magnetic resonance imaging.
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deescalated to a moderately effective therapy (e.g. 
glatiramer acetate),9 whereas pulsed immune 
reconstitution therapy (e.g. alemtuzumab) is 
administration of a highly active drug followed by 
long-term drug-free observation until new disease 
activity appears. Mitoxantrone could be used as 
both induction or pulsed immune reconstitution 
therapy, but there are no data supporting the use 
as pulsed immune reconstitution therapy. We 
decided not to include mitoxantrone in the pre-
sent article because the safety record includes fre-
quent severe adverse events, and, therefore, 
mitoxantrone is not recommended for routine use 
in patients with RRMS.10
In the present article we review the mechanism of 
action, efficacy and safety of the pulsed immune 
reconstitution therapies alemtuzumab, cladribine 
and, in brief, HSCT.
Alemtuzumab
Mechanism of action
Alemtuzumab is a humanized monoclonal anti-
body directed against the CD52 molecule, which 
is present on the cell surface of lymphocytes but 
also at lower levels on monocytes, macrophages, 
eosinophils and NK cells. Bone marrow-derived 
haematopoietic precursor cells lack CD52 on the 
surface, which allows lymphocyte reconstitution 
following treatment with alemtuzumab.11,12
Alemtuzumab causes a long-lasting depletion of 
lymphocytes, especially T-cells, mediated by 
three different mechanisms: antibody-dependent 
cell-mediated cytotoxicity, complement-depend-
ent cytotoxicity and apoptosis.13 Only minor 
effects are seen in cells of the innate immune sys-
tem. Neutropenia occurs in approximately 10% 
of patients after each treatment course; it is usu-
ally mild but can be severe in rare cases.14
Alemtuzumab preferentially depletes class-switched 
and unswitched memory B-cells.15 CD-19+ 
B-lymphocytes repopulate within approximately 
3–6 months and show an increase to 124–165% of 
baseline levels at 12 months. CD8+ cytotoxic 
T-cells will reach the lower normal level after 
9–12 months, while CD4+ T-cells repopulate at a 
slower rate, taking 1–2 years to reach the lower level 
of normal; and prolonged CD4+ T-cell depletion 
may last many years in some patients.16,17 Depletion 
is especially long-lasting for the subset of 
pro-inflammatory CD20 positive T-cells.18 
Monocytes reach baseline levels after 3 months.19,20
The faster B-cell than T-cell recovery might set 
the stage for unregulated B-cell expansion and 
antibody production in response to self-antigens, 
and after repletion the peripheral blood is domi-
nated by immature B-cells coupled to increased 
serum levels of BAFF (B-cell activating factor), 
which have previously been associated with 
B-cell-related autoimmune disorders.19,21
The overshoot in repletion of B-cells has also in 
MS been associated with development of second-
ary autoimmune disorders, although no direct 
relationship between B-cell repopulation kinetics 
and autoimmunity has been reported. After alem-
tuzumab treatment, T-cells are mainly memory 
T-cells originating from the pool of cells that 
escaped deletion and from cell populations in the 
bone marrow, lymphoid structures and thy-
mus.19,20 A high rate of cells proliferating from the 
pool of T-cells that escaped deletion is associated 
with a higher risk of development of secondary 
autoimmune disorders, while a higher proportion 
of newly generated T-cells tend to imply a lower 
risk of autoimmunity, probably because of the 
higher clonal diversity of the resulting T-cell pool.22 
The repletion after alemtuzumab includes expan-
sion of regulatory T-cells (Tregs) with increased 
suppressive function.
The long-lasting therapeutic benefit of alemtu-
zumab may involve a shift to an anti-inflamma-
tory cytokine balance.19,20,23
The rate and patterns of lymphocyte reconstitu-
tion are currently not thought to correlate with 
subsequent re-emergence of disease activity.24,25
Efficacy
One full course of alemtuzumab consists of 12 mg 
of alemtuzumab administered intravenously daily 
for five consecutive days and again one year later 
for three consecutive days.
Alemtuzumab is approved in the EU for treat-
ment of active MS, while in the USA the FDA 
has advised: ‘Because of its safety profile, the 
use of Lemtrada should generally be reserved 
for patients who have had an inadequate 
response to two or more drugs indicated for the 
treatment of MS.’
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Alemtuzumab has never been tested in large pla-
cebo-controlled trials, but has been compared 
with subcutaneous interferon-beta (INFβ)-1a 
and was found to be superior to INFβ-1a 44 μg 
three times weekly in one phase II study and two 
phase III studies, one with de novo treated patients 
and one in patients with breakthrough disease on 
a first-line drug. In these studies, assessment of 
the treatment effects was performed by a blinded 
neurologist, while the treating neurologist and the 
patient were not blinded.
In the phase II trial, alemtuzumab reduced 
3-month confirmed worsening on the Expanded 
Disability Status Scale (EDSS) by 71% and the 
annualized relapse rate (ARR) by 74% compared 
with INFβ (both p < 0.001).26 All comparisons 
between drugs regarding effects on relapses and 
disease worsening are shown as relative differ-
ences. The proportion of relapse-free patients 
treated with alemtuzumab was 80% and the pro-
portion free of worsening on the EDSS was 91%. 
The mean EDSS score decreased by 0.39. The 
study was extended up to 60 months, at which 
time 87% were still free of worsening on the EDSS, 
the mean EDSS had decreased by 0.30 and the 
proportion of relapse-free patients was 72%.27
The CARE-MS I study included treatment-naïve 
RRMS patients, who were randomized to receive 
either alemtuzumab (N = 376) or subcutaneous 
INFβ-1a 44 μg three times weekly (N = 187).28 
Alemtuzumab reduced the ARR by 55% (alemtu-
zumab 0.18 versus IFNβ-1a 0.39, p < 0.0001). 
Six-month confirmed disability worsening on the 
EDSS was 8% in the alemtuzumab group and 
11% in the IFNβ1a group (p = 0.22). The 
median change in the Multiple Sclerosis 
Functional Composite (MSFC) score was signifi-
cantly decreased by alemtuzumab (p = 0.01). 
Compared with IFNβ-1a, alemtuzumab signifi-
cantly reduced the proportion of patients with 
gadolinium-enhancing lesions and new or enlarg-
ing T2-hyperintense lesions, and the median 
parenchymal brain volume loss. Disease-free sta-
tus [no evidence of disease activity (NEDA-3): no 
relapse, no 3-month sustained change in EDSS 
score, and no new MRI lesions] after 2 years was 
achieved in 39% of the patients.28
The CARE-MS II study was performed in patients, 
who previously had been treated with a disease-
modifying drug, with similar study design, but 
slightly different inclusion criteria as those of 
CARE-MS I. A total of 426 patients were rand-
omized to receive alemtuzumab and 202 to receive 
subcutaneous INFβ-1a 44 μg three times weekly.29 
An additional third arm in CARE-MS II using 
infusion of 24 mg alemtuzumab was terminated 
early. Alemtuzumab significantly reduced the ARR 
by 49% (alemtuzumab 0.26 versus IFNβ-1a 0.52, 
p < 0.0001) and 6-month confirmed disability 
worsening on the EDSS by 42% (alemtuzumab 
13% versus IFNβ-1a 21%; p = 0.0084) (Table 1). 
Also gadolinium-enhancing lesions, new or enlarg-
ing T2-hyperintense lesions and parenchymal 
brain volume loss were significantly reduced by 
alemtuzumab compared with IFNβ-1a. NEDA-3 
after 2 years was achieved in 39% of the patients.29
Additional analyses of the data from the 
CARE-MS II study showed that more alemtu-
zumab-treated patients achieved 6-month con-
firmed disability improvement on the EDSS 
compared to IFNβ-1a.30
Quality-of-life (QoL) using the Functional 
Assessment of Multiple Sclerosis (FAMS), 
European Quality of Life-5 Dimensions (EQ-5D) 
and its visual analogue scale (EQ-VAS), and the 
Table 1. Efficacy of alemtuzumab and cladribine.
ARR (relative 
reduction of 
relapses)
Relative reduction 
of 6-month EDSS 
worsening
2-year 
NEDA-3
ARR in 
years 3–4
Long-term 
EDSS 
worsening
Alemtuzumab* 0.18; (55%)† §§ 30%† (NS) 30% 0.17 18%a
Alemtuzumab** 0.26; (49%)† §§ 42%† § 32% 0.23 23%a
Cladribine# 0.14; (58%)§§ 47%§ 47% 0.15 13%b
ARR: annualized relapse rate; NEDA: No evidence of disease activity; EDSS: Expanded Disability Status Scale; *CARE-MS I 
study; **CARE-MS II study; #CLARITY study (placebo-controlled); † Compared with IFN-β1a; aafter 5 years; bafter 4 years; §p 
< 0.001; §§p < 0.01; NS: not significant.
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36-Item Short-Form Survey (SF-36), was 
improved in patients treated with alemtuzumab 
compared with IFNβ-1a.31
In the 5-year extension of the CARE-MS I study, 
the majority of patients (68.5%) received no addi-
tional treatment after their initial two courses of 
alemtuzumab. However, 31.5% of the patients 
received additional alemtuzumab cycles: 22.1% 
received one additional cycle, 8.0% two additional 
cycles and 1.4% received three additional cycles.
ARR remained low (0.14–0.19). After 5 years, 
80% of patients were free from 6-month con-
firmed disability worsening and 33% achieved 
6-month confirmed disability improvement. The 
majority of patients attained NEDA-3 annually in 
the extension (62% in year 3, 60% in year 4 and 
62% in year 5).32
In the 5-year extension of CARE-MS II, 58% had 
only received the initial two courses of alemtu-
zumab. However, 42.0% of the patients received 
additional alemtuzumab cycles: 30.1% received 
one additional cycle, 10.4% two additional cycles 
and 1.6% received three additional cycles.
ARR remained low (0.18–0.23). After 5 years, 
77% were stable and 26% achieved 6-month con-
firmed disability improvement. A large propor-
tion of patients attained NEDA-3 annually in the 
extension (53% in year 3, 54% in year 4, and 
58% in year 5), and 27% of the patients had 
NEDA-3 after 5 years.33
In an observational study of 87 patients treated 
with alemtuzumab with a median follow-up of 
7 years, most patients only required two cycles of 
alemtuzumab. After 87 months 68% of the 
patients had either improved or stable EDSS 
scores, while 32% had worsened one point in 
EDSS score sustained over 6 months.34
Safety
Infusion reactions occurred in the majority of 
patients, of whom 3% experienced serious reac-
tions,28,29 and in the first clinical trials patients 
experienced transient increases in MS symptoms 
associated with cytokine release,35 which can be 
avoided by pretreatment with corticosteroids and 
antihistamines.
The major concern with the use of alemtuzumab 
is the high risk of developing secondary autoim-
munity (Table 2), which occurred in 48% over a 
median 7-year follow-up (range 33–144 months).34 
More than 40% of patients developed thyroid dis-
orders and the rate of immune thrombocytopenia 
was 3.4%.34 A few patients have encountered 
immune-mediated nephropathies, including cases 
of Goodpasture syndrome (anti-glomerular base-
ment membrane) and membranous nephropathy, 
two of whom needed a renal transplant.27–29 
Autoimmune disorders peak 2–3 years after the 
first dose of alemtuzumab,28,29 but may occur 
more than 5 years after the last dose.34
Profound disease activity has been reported in a 
few patients 3–6 months after administration of 
alemtuzumab and has been ascribed to early 
B-cell repopulation and peripheral expansion fol-
lowing alemtuzumab treatment.36
Because of the drug safety profile, its prescription 
is restricted by the Risk Evaluation and Mitigation 
Table 2. Tolerability of alemtuzumab and cladribine.
Administration-related 
adverse effects
Secondary 
autoimmune 
disorders
Herpes 
zoster 
infections
PML Secondary 
cancer 
development
Long-term 
monitoring of 
adverse effects
Alemtuzumab >90%* Thyroid disease 
>40%
ITP: 1–3%
Nephropathy <1%
6%§ PML not 
reported in 
MS
Not increased 4 years after last 
administration
Cladribine 0 0 1.9% PML not 
reported in 
MS
Not increased No
*Manageable with appropriate premedication and modification of infusion; § a proportion of patients (~50%) received aciclovir prophylaxis.
ITP: autoimmune thrombocytopenia; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy.
Therapeutic Advances in Neurological Disorders 12
6 journals.sagepub.com/home/tan
Strategy (REMS) Program, which includes not 
only patients, but also physicians. Moreover, as 
rare fatal cases have occurred, a continuous evalu-
ation of possible signs and symptoms of thrombo-
cytopenia is mandatory. As part of the programme, 
a monthly laboratory assessment of complete 
blood counts, testing of serum creatinine and urine 
analysis is carried out, and determination of thy-
roid functionality is recommended every 3 months 
until 48 months after the last dose.
Biomarkers that would allow the identification of 
patients at risk for the development of secondary 
autoimmune diseases are not yet available. Initial 
claims that secondary autoimmunity was associ-
ated with increased pretreatment blood levels of 
interleukin-21 were not confirmed in subsequent 
studies using different immunoassays.37,38
There is also an increased risk of infection, especially 
for herpes zoster, and antiviral prophylaxis with acy-
clovir is recommended at least one month after 
alemtuzumab therapy. Rare serious adverse event 
reported postmarketing include patients with Listeria 
meningitis, one fatal, occurring a few days after the 
first infusion cycle of alemtuzumab,39,40 and one 
lethal case of disseminated necrotizing leukoenceph-
alopathy occurring 8 months after alemtuzumab 
treatment.41 Haemophagocytic lymphohistiocytosis 
was reported in two patients with MS treated 
with alemtuzumab.42 Other rare adverse effects are 
haemolytic anaemia43 and alopecia.44
Progressive multifocal leukoencephalopathy 
(PML) was not reported in any MS patient 
treated with alemtuzumab but has occurred in 
patients treated with alemtuzumab for malignant 
diseases.45,46 Another adverse event after alemtu-
zumab administration is acute acalculous chole-
cystitis, but whether this has an infectious 
pathogenesis is still uncertain.47
Female patients need to practice effective contra-
ception and avoid pregnancy until 4 months after 
treatment with alemtuzumab.
After alemtuzumab treatment, serum antibodies 
against common viruses remained detectable, 
and vaccine responses were normal to both novel 
and recall antigens within 6 months of alemtu-
zumab administration.48
Anti-alemtuzumab antibodies developed in 86% 
and 81% of patients after the second treatment in 
CARE-MS I and CARE-MS II, respectively, and 
the prevalence and mean peak anti-alemtuzumab 
antibody titres were higher after the second than 
after the first treatment course.28,29 Anti-
alemtuzumab antibodies did not appear to influ-
ence efficacy, safety or lymphocyte depletion and 
repopulation.49 However, anti-alemtuzumab 
antibodies may still have an effect in some 
patients, in whom lymphocyte depletion after 
alemtuzumab therapy may be less complete even 
after the first alemtuzumab cycle.50 This is most 
likely explained by individual differences in the 
efficiency of effector mechanisms or trogocytosis, 
which is a process in which antibodies are stripped 
from the cell surface by other cell types.51
Cladribine
Mechanism of action
Cladribine (2-chloro-2′deoxy-β-D-adenosine) is 
a synthetic deoxyadenosine analogue with substi-
tution of a hydrogen atom with chlorine at the 
2-position of the purine ring. This substitution 
makes the nucleoside analogue resistant to degra-
dation by adenosine deaminase, an enzyme that 
metabolizes and clears the naturally occurring 
deoxynucleosides.
The dosage of cladribine tablets is 3.5 mg/kg over 
2 years, with 1.75 mg/kg being administered each 
year. The yearly treatment includes two treat-
ment periods, one at the start of the first month 
and the other starting in the second month, each 
comprising 4 or 5 days in which a single 10 or 
20 mg dose of cladribine tablets is taken, depend-
ing on bodyweight.
Oral bioavailability of cladribine varies between 
37% and 55%.52 Cladribine has biphasic half-life 
elimination. The mean terminal half-life with 
normal renal function is 5.6–7.6 h.53
Cladribine enters the cell via nucleoside transporter 
proteins. Inside the cell, cladribine is activated 
through phosphorylation by the enzyme deoxycyti-
dine kinase (DCK) to 2-chloro-2′deoxy-β-D-
adenosine monophosphate and can be inactivated 
through de-phosphorylation by the enzyme 
5′-nucleotidase (5′-NTase).53,54 The selective effect 
on lymphocytes is explained by a high concentra-
tion of DCK and a low concentration of 5′-NTase 
compared with other cells, resulting in intracellular 
accumulation of activated cladribine.53
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The exact mechanism of action of cladribine in 
dividing and non-dividing cells is still unknown, 
but it has immunosuppressive effects and has 
been approved for the treatment of hairy cell leu-
kaemia since 1980.55 Furthermore, 2-chloro-
2′deoxy-β-D-adenosine monophosphate is 
converted to active triphosphate deoxynucleo-
tides (CdATP) by DCK and this accumulation 
interferes with DNA repair of single-stranded 
breaks, rendering cell death.56 In dividing cells, 
CdATP can also be incorporated into the DNA, 
impairing transcription. Cladribine causes apop-
tosis through the caspase system, in which the 
cytochrome C and apoptotic protease-activating 
factor activate caspase-3 and damage DNA.57 
These cytotoxic mechanisms interfere with the 
synthesis and repair of DNA and, therefore, tar-
get both resting and dividing lymphocytes.
Work on a human leukaemia cell line showed that 
cladribine inhibits global DNA methylation.58 
There is growing evidence that cladribine may 
have epigenetic properties by turning off onco-
genic signalling.59 Cladribine may also influence 
the cytokine milieu independently of the effect on 
lymphocytes, inhibiting pro-inflammatory cells 
and cytokines.53
Treatment with cladribine leads to a preferential 
and sustained reduction in lymphocytes, resulting 
in long-lasting partial depletion of circulating 
CD4+ T-cells.53,54 Cladribine has also induced a 
rapid depletion of CD56+ NK cells that, how-
ever, rapidly recovered and were even slightly 
above baseline at 6 and 12 months.60
Within the B-cell population the magnitude and 
kinetics of depletion vary substantially. The ratio 
of DCK to 5′-NTase expression was particularly 
high in mature, memory and notably germinal 
centre B-cells, but not in plasma cells. Thus, 
cladribine depletes class-switched and unswitched 
memory B-cells to levels comparable with 
alemtuzumab.15
Median CD4+ T-cell counts in patients treated 
with a cumulative dose of cladribine of 3.5 mg/kg 
reached a nadir at 4 months and then gradually 
increased. After treatment in year 2, a nadir was 
reached at 60 weeks and then gradually recov-
ered, exceeding the threshold of 0.350 × 109 cells/L 
by 120 weeks. At the end of year 2 some patients 
had still not reached the lower limit, but reconsti-
tution continued and at 4 years almost all patients 
had reached the lower limit of normal. The 
decrease in CD8+ T-cells is less pronounced 
compared with the decrease in CD4+ T-cells, 
and overall did not drop below the lower limit of 
normal. Furthermore, the recovery is faster, 
meaning that the CD4+/CD8+ ratio is tempo-
rarily decreased.
In addition, cladribine treatment led to changes 
in the absolute cell count and relative distribution 
of many lymphocyte subsets, but the relationship 
to clinical effects is not known.
Cladribine also depleted various innate immune 
cells, including NK cells and monocytes, although 
to a lesser extent than lymphocytes. Reductions 
in neutrophils, platelets and erythrocytes were 
modest, and mean levels of these cells remained 
within the normal range throughout the treat-
ment period.60
Cladribine can cross the blood–brain barrier 
(BBB) and the concentration in the cerebrospinal 
fluid is 25% of that in plasma.53 It is plausible that 
cladribine reduces disease activity in MS, at least 
in part, by depleting circulating memory B-cells 
and thus reducing the influx of these cells into the 
central nervous system (CNS),60 and that cladrib-
ine may deplete CNS-resident immune cells in 
vivo; however, the effects of cladribine in the 
CNS are virtually unknown.
Efficacy
In the CLARITY trial, treatment with cladribine 
tablets significantly reduced the ARR (0.14 for the 
group receiving 3.5 mg/kg and 0.15 for the 5.25 mg/
kg versus 0.33 for the placebo group; relative reduc-
tions were 58% and 55%, respectively; p < 0.001).61 
Treated patients had a higher relapse-free rate 
(80% and 79%, respectively) versus placebo-treated 
patients (60.9%) (p < 0.001) and had a signifi-
cantly lower risk of 3-month and 6-month sus-
tained disability worsening.62 NEDA-3 after 2 years 
was achieved in 178 (44%) of 402 patients in the 
cladribine 3.5 mg/kg group, 189 (46%) of 411 
patients in the cladribine 5.25 mg/kg group and 60 
(16%) of 379 patients in the placebo group (OR 
4.28, 3.05–6.02 for the 3.5 mg/kg group; 4.62, 
3.29–6.48 for the 5.25 mg/kg group; both p < 
0.0001).62 Subgroup analysis of patients with high 
disease activity (⩾2 relapses in de novo treated 
patients or ⩾1 relapse plus MRI changes in patients 
on a DMT) indicated greater responsiveness to 
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cladribine 3.5 mg/kg in this patient subgroup.63 
The clinical findings were underscored by the 
results of MRI studies.64 Patients in the 3.5 mg/kg 
or 5.25 mg/kg cladribine groups had fewer lesions 
per patient per scan for: T1 gadolinium-enhancing 
lesions (mean 0.12 and 0.11 versus 0.91), active T2 
lesions (mean 0.38 and 0.33 versus 1.43) and com-
bined unique lesions (mean 0.43 and 0.38 versus 
1.72); all p < 0.001 versus placebo.65
Of the 1184 patients that completed the CLARITY 
trial, 867 (73%) were enrolled in the 2-year 
CLARITY EXTENSION study. AAR remained 
low in patients who in the CLARITY trial were 
treated with cladribine 3.5 mg/kg (ARR 0.14; 95% 
CI: 0.12–0.17), independently of whether patients 
were randomized to placebo (N = 98) (ARR 0.15; 
95% CI: 0.09–0.21) or cladribine 3.5 mg/kg (N = 
186) (ARR 0.10; 95% CI: 0.06–0.13) in the 
CLARITY EXTENSION (NS). The proportions 
of relapse-free patients were 76% in the placebo 
group and 81% in the cladribine 3.5 mg/kg group 
(NS), and the proportions of patients who remained 
free of confirmed 3-month EDSS worsening were 
72% in the placebo group and 77% in the cladrib-
ine 3.5 mg/kg group (NS). Of importance, the effi-
cacy was maintained even after the lymphocyte 
count had reached the lower limit of normal.66
The mean number of T1 gadolinium-enhancing 
lesions was significantly higher and the propor-
tion of patients with no active T2 lesions was sig-
nificantly lower in the placebo group compared 
with the cladribine 3.5 mg/kg group.67
In another placebo-controlled trial, cladribine was 
studied in 903 patients with the first demyelinating 
episode, of whom 37% fulfilled the McDonald 
2010 criteria for MS, while 63% were clinically 
isolated syndrome (CIS) patients. The primary 
endpoint was conversion to clinically definite MS. 
The risk reduction for time to conversion to clini-
cally definite MS was 67% for 3.5 mg/kg and 62% 
for 5.25 mg/kg [hazard ratio (HR) 0.33, 0.21–0.51 
and 0.38, 95% CI: 0.25–0.58, respectively, both p 
< 0.0001], which in fact is the highest risk reduc-
tion reported in any placebo-controlled trial in 
patients with a first demyelinating episode.68
Cladribine 3.5 mg/kg was also compared with pla-
cebo as add-on therapy in relapsing patients with 
clinical activity despite IFN-β treatment in a 
96-week phase II study. The study was, however, 
discontinued because of frequent (64%) grade 3/4 
lymphopenia (lymphocyte count < 500 cells/mm3) 
in patients treated with the combination of cladrib-
ine and IFNβ. Add-on of cladribine reduced the 
risk of relapse by 63% compared to placebo.69
Safety and tolerability
Cladribine tablets were well tolerated with no 
symptoms in relation to drug administration. 
Across all studies cladribine showed a favourable 
safety profile. As a reflection of the mechanism of 
action of cladribine,53 lymphopenia was more fre-
quent in the cladribine groups (combined clad-
ribine group 27% versus 1.8% in placebo) in the 
CLARITY trial.61
Following treatment with cladribine 3.5 mg/kg, 
86–89% of patients recovered to grade 0 or 1 
lymphopenia by week 48 in each treatment year. 
At the end of year 2, severe lymphopenia (grade 3 
or 4) was only seen in 2.3%.70 In patients with a 
normal baseline absolute lymphocyte count 
(ALC), only 0.5% had lymphopenia grade 3 at 
the end of the year; in patients who at the start of 
year 2 had lymphopenia grade 0 or 1, only 0.8% 
had grade 3 lymphopenia at the end of year 2.
The EU Summary of Product Characteristics 
(SMPC) for Cladribine Tablets states that the 
treatment should only be initiated in patients who 
have a normal ALC, and the treatment in year 2 
should only be administered to patients with grade 
0 or 1 lymphopenia (ALC ⩾ 0.8 × 109 cells/L). 
The course in year 2 can be delayed for up to 
6 months to allow for recovery of lymphocytes, but 
if recovery takes more than 6 months, the patient 
should not receive further treatment.71
In the cladribine group, severe neutropenia was 
reported in three patients, of whom one also had 
severe thrombocytopenia and pancytopenia; the 
patient turned out to have a reactivation of latent 
tuberculosis and subsequently died.70 As it was 
conceivable that cladribine had contributed to 
this reactivation, screening measures for tubercu-
losis have been implemented before treatment 
and retreatment. The maximum decrease in ALC 
of 45–64% compared to baseline, and the median 
reduction in ALC from baseline to the end of the 
second treatment period was 43–48%.61 The total 
incidence of serious adverse events was 8.4% in 
the cladribine 3.5 mg/kg group, 9.0% in the 
5.25 mg/kg group and 6.4% in the placebo 
group.61 Infections or infestations were reported 
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as serious adverse events in 2.3% (cladribine 
3.25 mg/kg), 2.9% (cladribine 5.25 mg/kg) and 
1.6% (placebo), and the incidence of infections in 
the cladribine groups showed an inverse correla-
tion with the lowest lymphocyte count. Herpes 
zoster infections, all dermatomal restricted, devel-
oped in 20 patients who received cladribine, com-
pared to none in the placebo group.61 Herpes 
zoster infections were most frequently seen in 
patients suffering lymphopenia grade 3 or 4,61 
although this was not evident when serial lym-
phocyte counts were applied.70 Nevertheless, pro-
phylactic treatment for herpes is recommended in 
patients with lymphopenia grade 3 or 4.
PML has not been reported in MS patients 
treated with cladribine, but has been observed in 
patients treated with cladribine for malignant 
diseases.72
In the CLARITY study, neoplasms were found only 
in the cladribine group (four cancers and five benign 
uterine leiomyomas) versus none in the placebo 
group.61 However, the observed number of cancers 
during the study did not differ from the expected 
number obtained from a reference population stand-
ardized for country, gender and age [standard inci-
dence rate (SIR)],70 and comparison with other 
DMTs shows that the number of malignancies in 
CLARITY was comparable.73 Accordingly, obser-
vations from all clinical trials and observational stud-
ies of cladribine in MS do not support any suspicion 
of an increase in rate of cancers.
There were four deaths during the CLARITY 
study and two after discontinuation, equally dis-
tributed across the three study groups.61
Data on human teratogenicity are sparse, but 
cladribine inhibits DNA synthesis and should 
therefore not be administered during pregnancy.53 
Pregnancies have occurred during the clinical 
studies of cladribine in MS with various out-
comes, most frequently induced abortion, but 
also delivery of healthy babies.70 Female patients 
need to practice effective contraception and avoid 
pregnancy until 6 months after treatment with 
cladribine. Male patients must take precautions 
to prevent pregnancy of their female partner dur-
ing cladribine treatment and for at least 6 months 
after the last dose.
There is only limited experience with use of other 
DMTs after treatment with cladribine, and 
knowledge of long-term safety in MS patients 
treated with cladribine is sparse.
After treatment with a pulsed immune reconstitu-
tion therapy it is advisable to avoid cell-depleting 
treatment until the lymphocyte count has reached 
lower limits of normal and use, for example, the 
injectable platform therapies. With a normal cell 
count and no signs of immune deficiency, treat-
ment with other disease-modifying drugs such as 
dimethyl fumarate, natalizumab or ocrelizumab 
would appear to be well tolerated.
Haematopoietic stem cell transplantation
Intense immunosuppression followed by autolo-
gous HSCT has been used to treat patients with 
MS during the last 2–3 decades.74 The most com-
monly used immunosuppressive, conditioning regi-
men is the so-called BEAM, including treatment 
with carmustine, etoposide, cytarabine and mel-
phalan. A less intensive conditioning regimen has 
consisted of cyclophosphamide, sometimes com-
bined with fludarabine. Surviving cells are further 
depleted by infusion of polyclonal anti-thymocyte 
globulin (ATG).74 After HSCT there is extensive 
regeneration of the circulating T-cell pool with 
emergence of a novel repertoire of CD4+ T-cells, 
whereas CD8+ predominantly emerge from 
expansion from the preexisting T-cell repertoire.75 
As a result, there are increased numbers of regula-
tory T-cells, diminished pro-inflammatory T-helper 
type 17 responses and loss of the subset of mucosal-
associated invariant T-cells after HSCT.76,77 
Interestingly, disease activity after HSCT has been 
associated with emergence of a more clonally 
restricted CD4+ T-cell repertoire after HSCT.75
Whereas HSCT was initially used primarily in 
patients with progressed disease, the trend during 
the last 10–15 years has been to use HSCT in 
patients with less-progressed disease, primarily 
patients with RRMS, and to use less intense con-
ditioning regimens. Because of this, the mortality 
has decreased from 5–7% to 1.3%,74 and in the 
most recent years the reported mortality after 
HSCT has been below 1%.
A study of 19 patients, four of whom had RRMS 
with an average EDSS of 6.4, followed for a mean 
observation time of 102 months after HSCT, 
found that 95% of the patients were free of dis-
ease progression in EDSS and 64% experienced 
neither relapses nor worsening on the EDSS.78
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In a study in 21 patients with RRMS using non-
myeloablative conditioning with cyclophospha-
mide, with a median observation time of 37 months, 
none of the patients progressed one point on the 
EDSS, 76% were free of relapses and 62 had 
NEDA-3.79
An Italian multi-centre collaboration using BEAM/
ATG included 74 patients between 1996 and 
2008, of whom 33 had RRMS with a mean EDSS 
of 6.3. After a mean observation time of 48 months, 
74% of the patients remained free of worsening in 
EDSS, and of 18 patients followed for more than 
7 years 44% remained stable or had an improve-
ment in EDSS. The mortality was 2.7%.80
In a Swedish study of 48 patients, efficacy assess-
ment was performed in 41 patients, of whom 34 
patients (83%) had RRMS, with a mean follow-
up time of 47 months, 4 patients (10%) experi-
enced relapses after HSCT and the ARR was 
0.03. Eight patients progressed in EDSS score, 
while one patient improved. At 5 years NEDA-3 
was 68%.81 No mortality was recorded. Acute 
toxicity during hospitalization included the well-
known and expected side-effects of alopecia, 
anaemia, thrombocytopenia and leukopenia, 
and were seen in almost all patients. A little less 
than half of the patients experienced fever with 
bacteraemia, neutropenic fever was seen in 
about one-third and one patient was diagnosed 
with invasive fungal infection. Eight patients 
(17%) experienced herpes zoster reactivation, 
four patients (8.3%) developed thyroid disease, 
one patient developed Crohn’s disease and one 
patient developed alopecia areata. No patient 
developed malignancy during the follow-up 
period.81
Recently, a study of 24 patients with RRMS with 
EDSS 3.0–5.5 were treated with HSCT using 
BEAM. Median follow-up was 62 months (range 
12–72). Progression-free survival was 91% (90% 
CI: 75–97%), relapse-free survival was 87% (90% 
CI: 70–95%), and no evidence of disease activity 
(NEDA-3) was reported in 69% (90% CI: 50–82%) 
(Figure 2). No HSCT-related deaths occurred.82
A meta-analysis of 15 studies comprising 764 
patients undergoing HSCT for MS integrated 
results of both efficacy and safety. They found a 
pooled disability progression rate of 23% and a 
pooled proportion of patients maintaining 
NEDA-3 of 68% at 5 years after the procedure. 
The treatment-related mortality was 2.1%, with a 
decrease in most recent years.83
Conclusion
The advantages and potential disadvantages of con-
tinuous immunosuppression and pulsed immune 
reconstitution therapy are shown in Table 3. 
Advantages include infrequent administration and 
efficacy beyond the period of active treatment. Long-
term remission is seen in a considerable proportion 
of patients after one full course of alemtuzumab, and 
in fact 58.0–68.5% did not need additional cycles of 
alemtuzumab for 5 years.32,33 After cladribine 3.5 mg/
kg in the 2-year randomized placebo-controlled 
study, 75.1% of patients remained relapse-free in 
Figure 2. Proportion of patients with disease-free status (NEDA-3) in patients treated with cladribine,58 
alemtuzumab,32 and three recent trials of HSCT (HALT-MS77; Swedish trial76; and Burt74).
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years 3 and 4 without further treatment, but the 
effect after year 4 is not known.84
Another advantage is the possibility to become 
pregnant and lactate 4 months (alemtuzumab) or 
6 months (cladribine) after the last administration 
of the drug.
Potential disadvantages of pulsed immune recon-
stitution therapy include reactivation of latent 
infections such as tuberculosis, and risk of herpes 
zoster which is associated with severe lymphopenia. 
Also, several rare infections such as Listeria menin-
gitis have been reported. The main disadvantage in 
alemtuzumab-treated patients is the risk of second-
ary immune-mediated disorders, which, however, 
has not been reported with cladribine. Also, the 
long-term monitoring required after the last admin-
istration of alemtuzumab is a drawback.
The development of secondary cancers, which 
initially was suspected for cladribine, does not 
seem to be related to pulsed immune reconstitu-
tion therapy.
Pulsed immune reconstitution therapy is an option 
as initial therapy in RRMS patients with high dis-
ease activity, which in untreated patients may be 
defined as two or more relapses within the last 
year, and in patients on treatment with another 
DMT as two or more relapses or one relapse and 
significant MRI activity. However, pulsed immune 
Table 3. Potential advantages and disadvantages comparing continuous immunosuppression and pulsed immunosuppression.
Continuous immunosuppression (e.g. 
dimethyl fumarate, teriflunomide, fingolimod, 
natalizumab)
Pulsed immunosuppression (e.g. 
alemtuzumab, cladribine)
Clinical efficacy duration Only during active treatment Extends beyond period of active 
treatment
Infections:
• PML
•  Reactivation of latent 
infections, e.g. tuberculosis
• Herpes zoster
Risk of PML with some treatments
Low risk of reactivation
Low to moderate risk
Low risk of PML
Higher risk of reactivation
Higher risk during lymphopenia
Live vaccines Contraindicated May not be contraindicated after immune 
reconstitution
Risk of cancer Long-term immunosuppression may increase 
risk of cancer
No indication of increased risk of cancer
Pregnancy Not recommended* Pregnancy safe after drug elimination 
(4 months after alemtuzumab and 
6 months after cladribine administration)
Lactation Not recommended Lactation safe after drug elimination (see 
above)
Treatment escalation in case of 
suboptimal treatment response
Well-documented and generally well tolerated 
using risk-mitigation strategies
Only limited experience
Risk of adverse effects after 
discontinuation of treatment
Short-term risk only Long-term risk even after immune 
reconstitution
Long-term tolerability Well-known and generally good. Serious 
infections occur, and PML has been reported 
for natalizumab and in rare cases for fingolimod 
and dimethyl fumarate
Uncertain
*The general rule is that pregnancy is not recommended. However, for some drugs, such as natalizumab, use during pregnancy should be based on 
a benefit–risk evaluation taking into account the patient’s clinical condition and the possible return of disease activity after stopping the medicinal 
product.
PML: progressive multifocal leukoencephalopathy.
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reconstitution therapy might also be considered as 
the initial therapy in early RRMS with negative 
prognostic factors and active disease from onset 
(not only patients with two relapses in the previous 
year, but also patients with a relapse with incom-
plete recovery associated with new or enhancing 
lesions in MRI). If pulsed immune reconstitution 
therapy has been decided, the choice between 
alemtuzumab and cladribine should be based on 
efficacy balanced against the risks. Figure 3 depicts 
the authors’ opinion of the efficacy and tolerability 
of cladribine, alemtuzumab and HSCT. The 
potentially higher efficacy of alemtuzumab com-
pared to cladribine, although still only hypothetical 
as no head-to-head studies have been performed, 
comes at the costs of more frequent and severe 
adverse events. In our opinion, based on the pub-
lished data, the evidence of long-term efficacy is 
increasing from cladribine to alemtuzumab and is 
best for HSCT.
Whereas treatment with intense immunosuppres-
sion supported with autologous HSCT can estab-
lish long-term disease-free status and, in some 
patients, possibly even permanent remission, it 
still needs to be shown that pulsed immune recon-
stitution therapy with alemtuzumab or cladribine 
can also induce long-term or even permanent 
drug-free remission.85 However, as the most 
encouraging results with HSCT have been 
reported in very early RRMS, induction of long-
term NEDA-3 with pulsed immune reconstitu-
tion therapy could at least be an exciting possibility 
in some patients, if therapy is given early in the 
disease course.
Presently, the experience with long-term outcome 
for these therapies is missing and must be 
addressed in long-term follow-up studies.
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